LON:DDDD 4D pharma (DDDD) Share Price, News & Analysis Add Compare Share Share Today's Range N/A50-Day Range 16.66▼ 16.6652-Week Range N/AVolume1.21 million shsAverage Volume2.96 million shsMarket Capitalization£30.05 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get 4D pharma alerts: Email Address Ad Golden CrestBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.>> Get Your FREE Wealth Protection Guide << About 4D pharma Stock (LON:DDDD)4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. In addition, the company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate MRx0518; strategic collaboration agreement with University of Texas MD Anderson for discovery and development of LBPs in oncology; and Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda, MRx0518 in patients with solid tumors, and to discover and develop LBPs for vaccines. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.Read More Ad Golden CrestBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.>> Get Your FREE Wealth Protection Guide << DDDD Stock News HeadlinesAugust 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for 4D Molecular Therapeutics Amidst Strong Financials and Promising PipelineJuly 26, 2024 | markets.businessinsider.comBuy Rating for 4D Molecular Therapeutics: Promising Future Based on Product Efficacy and Strategic Growth ProspectsSeptember 7, 2024 | Weiss Ratings (Ad)“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.July 19, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Applied Therapeutics (APLT) and Oric Pharmaceuticals (ORIC)July 19, 2024 | markets.businessinsider.comBuy Rating for 4D Molecular Therapeutics Based on Promising Phase II Trial Results for 4D-150 Gene TherapyJuly 19, 2024 | msn.com4D Molecular Therapeutics Goes Neck To Neck With Rival, Shares New Phase 2 Data For Its Wet AMD CandidateJuly 19, 2024 | benzinga.comPeeling Back The Layers: Exploring 4D Molecular Therapeutics Through Analyst InsightsMarch 1, 2024 | markets.businessinsider.com4D Molecular Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)September 7, 2024 | Weiss Ratings (Ad)“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.February 7, 2024 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About 4D Molecular TherapeuticsFebruary 7, 2024 | msn.com4D Molecular Therapeutics up 3%, prices $300M equityFebruary 5, 2024 | marketwatch.com4D Molecular Shares Hit 52-Week High After 4D-150 Eye Treatment TrialFebruary 5, 2024 | realmoney.thestreet.comHow to Trade a Surging 4D Molecular TherapeuticsFebruary 5, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: 4D Molecular Therapeutics (FDMT), Boston Scientific (BSX)February 5, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Valeo Pharma (OtherVPHIF) and AbbVie (ABBV)January 30, 2024 | news.yahoo.comIndian pharma firm Dr Reddy's beats Q3 profit view on strong US, European businessesNovember 27, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Merus (MRUS), 4D Molecular Therapeutics (FDMT) and Inari Medical (NARI)November 11, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Xenon (XENE), Adverum Biotechnologies (ADVM) and 4D Molecular Therapeutics (FDMT)See More Headlines Receive DDDD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 4D pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/30/2020Today9/07/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:DDDD CUSIPN/A CIKN/A Webwww.4dpharmaplc.com Phone+44-113-8950130FaxN/AEmployees106Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (15.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-31,940,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-89.48% Return on Assets-42.64% Debt Debt-to-Equity Ratio39.50 Current Ratio5.21 Quick Ratio4.72 Sales & Book Value Annual Sales£718,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash Flow1.44 Book ValueGBX 18 per share Price / BookN/AMiscellaneous Outstanding Shares180,340,000Free FloatN/AMarket Cap£30.05 million OptionableNot Optionable Beta2.63 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Duncan Joseph Peyton (Age 53)CEO & Exec. Director Comp: $254kDr. Alexander James Stevenson Ph.D. (Age 51)Chief Scientific Officer & Exec. Director Comp: $218kMr. John Brendan Doyle (Age 45)Chief Financial Officer Ms. Fay WestonHead of Investor RelationsMr. Adrian MurrayGen. Counsel (Interim)Mr. Glenn DouradoExec. VP of Corp. Devel.Ms. Lucy ChristieVP of HRMr. Christophe CariteSr. VP of CMC & Process Devel.Ms. Imke MulderExec. VP of ResearchMore ExecutivesKey CompetitorsFutura MedicalLON:FUMTiziana Life SciencesLON:TILSVerseonLON:VSNMereo BioPharma Group plc (MPH.L)LON:MPHOpen OrphanLON:ORPHView All Competitors DDDD Stock Analysis - Frequently Asked Questions How were 4D pharma's earnings last quarter? 4D pharma plc (LON:DDDD) issued its quarterly earnings data on Wednesday, September, 30th. The company reported ($14.06) earnings per share for the quarter. How do I buy shares of 4D pharma? Shares of DDDD stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of 4D pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that 4D pharma investors own include Amigo (AMGO), Adamis Pharmaceuticals (ADMP), American Airlines Group (AAL), Boeing (BA), Cineworld Group (CINE), Cray (CRAY) and Omega Diagnostics Group (ODX). This page (LON:DDDD) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share 4D pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.